Goldhaber and colleagues (1) state that, based on the PREVENT (Prevention of Recurrent Venous Thromboembolism) trial (2), indefinite anticoagulation with warfarin should be standard practice in unprovoked DVT. This conclusion could be challenged for several reasons. PREVENT showed a statistically significant decrease in recurrent DVT, but not in overall mortality. Of the 8 deaths in the placebo group, only 2 were due to pulmonary embolism. Furthermore, 9 placebo recipients but only 4 warfarin recipients developed cancer, indicating that the slight increase in mortality in the placebo group may be due to neoplasia. Therefore, the risk for death from stopping anticoagulation seems to be less than 1% during the approximately 2-year median follow-up in the trial, probably the same as the risk for hemorrhagic death from anticoagulation. Lifelong anticoagulation is risky, is associated with significant morbidity and mortality, and may not be appropriate for all patients with unprovoked DVT.